TARGETING ANTIGEN PRESENTATION TO IMPROVE IMMUNOTHERAPY RESPONSES IN BREAST CANCER Cancer immunotherapies, particularly those targeting the PD-1/L1 axis, are revolutionizing treatment paradigms. Although these therapies have proven effective in a wide variety of solid tumors, response rates to single agent anti-PD-1/L1 in breast cancer have been underwhelming, centering around 5%-15% of treated patients. However, given the durable responses observed in other tumor types, finding ways to increase breast cancer sensitivity to immunotherapy is a valuable endeavor. Our recent work in breast cancer and melanoma has identified an important role for major histocompatibility complex-II (MHC-II) expression on tumor cells as a mediator of enhanced anti-tumor immunity and subsequent response to immunotherapies targeting the PD- 1/PD-L1 axis. Furthermore, our preliminary studies suggest that both MHC-I and MHC-II expression (antigen- presenting molecules) on breast tumor cells directly influences the tumor microenvironment through expanded anti-tumor immunity. We found that activation of the Ras/MAPK pathway suppresses the expression of both MHC-I and MHC-II, and therefore may be an actionable target for enhancing antigen presentation to promote anti-tumor immunity and potentiate immunotherapy responses. Based on these data, we have initiated trials in both metastatic triple-negative breast cancer (TNBC) and ER+ breast cancer testing the efficacy of this combination. In this proposal, we will perform clinical validation of the molecular effects of MEK inhibition with anti-PD-L1 in ongoing clinical trials at our institution, as well as perform direct translational studies exploring the immune mechanism behind MEK inhibition that promotes anti-tumor immunity. Our central hypothesis is that therapeutic modulation of antigen presentation via MEK inhibition will promote immunotherapy response in breast cancer through enhanced MHC-I and MHC-II responses. The proposed studies will elucidate mechanism, validate clinical utility and identify new targets for combinations of therapies that promote anti-tumor immunity through enhancing antigen presentation. Thus, this proposal will use a translational approach to bring rational combinations of immunotherapy and molecularly targeted agents to breast cancer patients.

Public Health Relevance

TARGETING ANTIGEN PRESENTATION TO IMPROVE IMMUNOTHERAPY RESPONSES IN BREAST CANCER This is a translational proposal that seeks to extend our preclinical studies, which identified synergy between MEK inhibitors and anti-PD-L1 immunotherapy, to two (2) human metastatic breast cancer trials testing the same combination. Tumor correlates associated with MEK inhibition in animals and subsequent response to immunotherapy will be evaluated in paired patient tumor biopsies; furthermore, we will perform laboratory experiments to optimize therapy sequence and schedule and confirm the functionality of MHC-II expression (induced by MEK inhibition) in tumor cells as a mediator of immunologic response. Successful completion of this work will elucidate possible clinical biomarkers for response or resistance to immunotherapy in breast cancer, as well as novel mechanisms of tumor immune-evasion.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098131-18
Application #
9984318
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2003-08-07
Project End
2024-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Mayer, Ingrid A; Abramson, Vandana G; Formisano, Luigi et al. (2017) A Phase Ib Study of Alpelisib (BYL719), a PI3K?-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin Cancer Res 23:26-34

Showing the most recent 10 out of 341 publications